Abstract
Campylobacter spp. are a common cause of bacterial gastroenteritis in Australia, primarily acquired from contaminated meat. We investigated the relationship between genomic virulence characteristics and the severity of campylobacteriosis, hospitalisation, and other host factors.
We recruited 571 campylobacteriosis cases from three Australian states and territories (2018–2019). We collected demographic, health status, risk factors, and self-reported disease data. We whole genome sequenced 422 C. jejuni and 84 C. coli case isolates along with 616 retail meat isolates. We classified case illness severity using a modified Vesikari scoring system, performed phylogenomic analysis, and explored risk factors for hospitalisation and illness severity.
On average, cases experienced a 7.5-day diarrhoeal illness with additional symptoms including stomach cramps (87.1%), fever (75.6%), and nausea (72.0%). Cases aged ≥75 years had milder symptoms, lower Vesikari scores, and higher odds of hospitalisation compared to younger cases. Chronic gastrointestinal illnesses also increased odds of hospitalisation. We observed significant diversity among isolates, with 65 C. jejuni and 21 C. coli sequence types. Antimicrobial resistance genes were detected in 20.4% of isolates, but multidrug resistance was rare (0.04%). Key virulence genes such as cdtABC (C. jejuni) and cadF were prevalent (>90% presence) but did not correlate with disease severity or hospitalisation. However, certain genes appeared to distinguish human C. jejuni cases from food source isolates.
Campylobacteriosis generally presents similarly across cases, though some are more severe. Genotypic virulence factors identified in the literature to-date do not predict disease severity but may differentiate human C. jejuni cases from food source isolates. Host factors like age and comorbidities have a greater influence on health outcomes than virulence factors.
Author summary This study focused on Campylobacter, a common cause of gastroenteritis in Australia. We explored the relationship between Campylobacter’s genomic characteristics and disease severity, hospitalisation, and host-related factors.
In 2018 – 2019, we collected data from 571 campylobacteriosis cases from Eastern Australia, focusing on demographics, health status, risk factors, and self-reported symptoms. We sequenced 422 C. jejuni and 84 C. coli case isolates and 616 retail meat isolates. We used a modified Vesikari scoring system to assess illness severity, performed phylogenomic analysis, and explored hospitalisation and severity risk factors.
Cases experienced an average 7.5-day period of diarrhoea with additional symptoms including stomach cramps, fever, and nausea. Older individuals (75+ years) had milder symptoms but a higher chance of hospitalisation. Those with chromic gastrointestinal conditions faced increased hospitalisation odds. Case isolates showed considerable diversity. Antimicrobial resistance genes were detected in some isolates, but multidrug resistance was rare. Virulence genes did not predict severity or hospitalisation, but some genes did differentiate between case and food source C. jejuni isolates. Host-related factors including age and comorbidities are more important in determining health outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The CampySource Project was funded by a National Health and Medical Research Council Grant (NHMRC GNT1116294), AgriFutures, Australian Government Department of Health, Food Standards Australia New Zealand, New South Wales Food Authority, Queensland Health, and ACT Health. Danielle Cribb is funded by an Australian Government Research Training Program (AGRTP) Scholarship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Australian National University Human Research Ethics Committee (Ref. 2016/426), Australian Capital Territory Health Human Research Ethics Committee (Ref. ETH.8.17.168), Hunter New England Human Research Ethics Committee (Ref. 17/08/4.03), Queensland Health Human Research Ethics Committee (Ref. RD007108), and the University of Melbourne Office of Research Ethics and Integrity (Ref. 1750366.1).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos